710286Allosterically Activated AntibodiesClosedGRD Proof of ConceptInnovate UKShyDen Biotechnology is developing a novel antibody format that harnesses the flexibility of antibodies to bind and ellicit novel functions. The Technology Strategy Board is funding the development of one of these platforms that has the potential to disrupt the antibody technology field and lead to a new generation of therapeutic and diagnostic antibodies. Future antibodies using ShyDen Biotech's new technology promise to be more potent but safer, exploiting targets previously deemed unsuitable with existing technologies.